Recombinant coagulation factor (rFVIIIFc)
ApprovedCompleted 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Hemophilia A
Conditions
Hemophilia A
Trial Timeline
Aug 29, 2017 → Aug 31, 2020
NCT ID
NCT03103542About Recombinant coagulation factor (rFVIIIFc)
Recombinant coagulation factor (rFVIIIFc) is a approved stage product being developed by Swedish Orphan Biovitrum for Hemophilia A. The current trial status is completed. This product is registered under clinical trial identifier NCT03103542. Target conditions include Hemophilia A.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03103542 | Approved | Completed |
Competing Products
20 competing products in Hemophilia A
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Emicizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| Emicizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| Emicizumab + rFVIIa + aPCC | Chugai Pharmaceutical | Phase 3 | 77 |
| Human Coagulation Factor VIII | Chugai Pharmaceutical | Phase 3 | 77 |
| Emicizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| Emicizumab + Factor VIII (FVIII) | Chugai Pharmaceutical | Phase 3 | 77 |
| Emicizumab | Roche | Phase 3 | 77 |
| HEMLIBRA | Johnson & Johnson | Pre-clinical | 23 |
| Emicizumab | Roche | Phase 3 | 77 |
| Emicizumab | Roche | Approved | 85 |
| Emicizumab | Roche | Phase 3 | 77 |
| SPK-8011QQ | Roche | Phase 1/2 | 41 |
| NXT007 | Roche | Phase 1/2 | 41 |
| Emicizumab Injection | Roche | Phase 2 | 52 |
| Bypassing Agents + FVIII Replacement | Roche | Pre-clinical | 23 |
| PF-06741086 + PF-06741086 + PF-06741086 + PF-06741086 | Pfizer | Phase 2 | 51 |
| Nonacog Alfa (Genetical Recombination) | Pfizer | Pre-clinical | 22 |
| Refacto AF | Pfizer | Pre-clinical | 22 |
| PF-06838435/ fidanacogene elaparvovec | Pfizer | Phase 3 | 76 |
| ReFacto AF | Pfizer | Phase 3 | 76 |